Your browser doesn't support javascript.
The next major emergent infectious disease: reflections on vaccine emergency development strategies.
Bai, Yu; Wang, Qian; Liu, Mingchen; Bian, Lianlian; Liu, Jianyang; Gao, Fan; Mao, Qunying; Wang, Zhongfang; Wu, Xing; Xu, Miao; Liang, Zhenglun.
  • Bai Y; Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.
  • Wang Q; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, China.
  • Liu M; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, China.
  • Bian L; Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.
  • Liu J; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, China.
  • Gao F; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, China.
  • Mao Q; Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.
  • Wang Z; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, China.
  • Wu X; NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, China.
  • Xu M; Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.
  • Liang Z; NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, China.
Expert Rev Vaccines ; 21(4): 471-481, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1647981
ABSTRACT

INTRODUCTION:

Major emergent infectious diseases (MEID) pose the most serious threat to human health. The research proposes targeted response strategies for the prevention and control of potential MEID. AREAS COVERED Based on the analysis of infectious diseases, this research analyzes pandemics that have a high probability of occurrence and aims to synthesize the past experience and lessons learned of controlling infectious diseases such as coronavirus, influenza, Ebola, etc. In addition, by integrating major infectious disease response guidelines developed by WHO, the European Union, the United States, and the United Kingdom, we intend to bring forward national vaccine R&D development strategies for emergency use. EXPERT OPINION We advise to establish and improve existing laws, regulations, and also prevention and control systems for the emergent R&D and application of vaccines in response to potential infectious diseases. The strategies would not only help increase the various abilities in response to the research, development, evaluation, production, and supervision of emergency vaccines, but also establish surrogate endpoint of immunogenicity protection in early clinical studies to enable a rapid evaluation of the efficacy of emergency vaccines.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Communicable Diseases / Hemorrhagic Fever, Ebola / Influenza, Human Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: Expert Rev Vaccines Journal subject: Allergy and Immunology Year: 2022 Document Type: Article Affiliation country: 14760584.2022.2027240

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Communicable Diseases / Hemorrhagic Fever, Ebola / Influenza, Human Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: Expert Rev Vaccines Journal subject: Allergy and Immunology Year: 2022 Document Type: Article Affiliation country: 14760584.2022.2027240